These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 31878968)

  • 41. Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort.
    Muurling M; Rhodius-Meester HFM; Pärkkä J; van Gils M; Frederiksen KS; Bruun M; Hasselbalch SG; Soininen H; Herukka SK; Hallikainen M; Teunissen CE; Visser PJ; Scheltens P; van der Flier WM; Mattila J; Lötjönen J; de Boer C
    J Alzheimers Dis; 2020; 76(3):1061-1070. PubMed ID: 32597806
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association of Cerebrospinal Fluid S100B Protein with Core Biomarkers and Cognitive Deficits in Prodromal and Mild Alzheimer's Disease.
    Christl J; Verhülsdonk S; Pessanha F; Menge T; Seitz RJ; Kujovic M; Höft B; Supprian T; Lange-Asschenfeldt C
    J Alzheimers Dis; 2019; 72(4):1119-1127. PubMed ID: 31683478
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Earliest amyloid and tau deposition modulate the influence of limbic networks during closed-loop hippocampal downregulation.
    Skouras S; Torner J; Andersson P; Koush Y; Falcon C; Minguillon C; Fauria K; Alpiste F; Blenow K; Zetterberg H; Gispert JD; Molinuevo JL;
    Brain; 2020 Mar; 143(3):976-992. PubMed ID: 32091109
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer's disease.
    Tardif CL; Devenyi GA; Amaral RSC; Pelleieux S; Poirier J; Rosa-Neto P; Breitner J; Chakravarty MM;
    Hum Brain Mapp; 2018 Feb; 39(2):971-984. PubMed ID: 29164798
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples.
    Wolfsgruber S; Molinuevo JL; Wagner M; Teunissen CE; Rami L; Coll-Padrós N; Bouwman FH; Slot RER; Wesselman LMP; Peters O; Luther K; Buerger K; Priller J; Laske C; Teipel S; Spottke A; Heneka MT; Düzel E; Drzezga A; Wiltfang J; Sikkes SAM; van der Flier WM; Jessen F;
    Alzheimers Res Ther; 2019 Jan; 11(1):8. PubMed ID: 30654834
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sex differences in Alzheimer's disease: plasma MMP-9 and markers of disease severity.
    Tsiknia AA; Sundermann EE; Reas ET; Edland SD; Brewer JB; Galasko D; Banks SJ;
    Alzheimers Res Ther; 2022 Nov; 14(1):160. PubMed ID: 36324151
    [TBL] [Abstract][Full Text] [Related]  

  • 47. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
    Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
    [TBL] [Abstract][Full Text] [Related]  

  • 48. β-amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly.
    Svenningsson AL; Stomrud E; Insel PS; Mattsson N; Palmqvist S; Hansson O
    Sci Rep; 2019 Aug; 9(1):11180. PubMed ID: 31371787
    [TBL] [Abstract][Full Text] [Related]  

  • 49. LAM Test: A New Cognitive Marker for Early Detection in Preclinical Alzheimer's Disease.
    García-Martínez M; Pozueta-Cantudo A; Lage C; Martínez-Dubarbie F; López-García S; Fernández-Matarrubia M; Corrales-Pardo A; Bravo M; Cavada NC; Anuarbe P; Infante J; López-Higuera JM; Rodríguez-Cobo L; Rodríguez-Rodríguez E; Butler CR; Sánchez-Juan P
    J Alzheimers Dis; 2024; 100(3):1039-1053. PubMed ID: 38943389
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Neurogranin, a synaptic protein, is associated with memory independent of Alzheimer biomarkers.
    Casaletto KB; Elahi FM; Bettcher BM; Neuhaus J; Bendlin BB; Asthana S; Johnson SC; Yaffe K; Carlsson C; Blennow K; Zetterberg H; Kramer JH
    Neurology; 2017 Oct; 89(17):1782-1788. PubMed ID: 28939668
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Associations of cigarette smoking with memory decline and neurodegeneration among cognitively normal older individuals.
    Wu P; Li W; Cai X; Yan H; Chen M;
    Neurosci Lett; 2020 Jan; 714():134563. PubMed ID: 31678372
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.
    Hohman TJ; Bell SP; Jefferson AL;
    JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Association of BDNF Val66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease.
    Lim YY; Maruff P; Barthélemy NR; Goate A; Hassenstab J; Sato C; Fagan AM; Benzinger TLS; Xiong C; Cruchaga C; Levin J; Farlow MR; Graff-Radford NR; Laske C; Masters CL; Salloway S; Schofield PR; Morris JC; Bateman RJ; McDade E;
    JAMA Neurol; 2022 Mar; 79(3):261-270. PubMed ID: 35099506
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume.
    Caldwell JZK; Berg JL; Cummings JL; Banks SJ;
    Alzheimers Res Ther; 2017 Sep; 9(1):72. PubMed ID: 28899422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults.
    Pettigrew C; Soldan A; Moghekar A; Wang MC; Gross AL; O'Brien R; Albert M
    Neuropsychologia; 2015 Nov; 78():63-72. PubMed ID: 26394023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
    Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
    Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade.
    Stricker NH; Dodge HH; Dowling NM; Han SD; Erosheva EA; Jagust WJ;
    Brain Imaging Behav; 2012 Dec; 6(4):599-609. PubMed ID: 22614327
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.